Kamari Pharma Announces New Data Presented at the 81st Annual Meeting of the Society for Investigative Dermatology Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita In vitro and in vivo...